Tarlatamab — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

7 Recruiting

5 Completed trials

9 Sponsors

17 Countries

Phase III

Phase II

Phase III: 5 Phase II: 8 Phase I/II: 1

Indications tested

Small cell lung cancer extensive stage 4 Small cell lung cancer recurrent 3 Small cell lung cancer 2 Small cell lung cancer metastatic 2 Small cell lung cancer limited stage 2

Sponsors using this IMP

Amgen Inc. 6 Academisch Ziekenhuis Maastricht 1 AIO-Studien gGmbH 1 Centre Leon Berard 1 ETOP IBCSG Partners Foundation 1 Fundacion GECP 1 Grupo Espanol De Tumores Neuroendocrinos 1 Institut Gustave Roussy 1 Intergroupe Francophone De Cancerologie Thoracique 1

All trials

14 total

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small … Pending

2025-522162-75-00 Phase II 1 country Academisch Ziekenhuis Maastricht
A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has … Pending

2025-522288-13-00 Phase II 4 countries ETOP IBCSG Partners Foundation
A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung can… Recruiting

2025-522437-65-00 Phase II 1 country AIO-Studien gGmbH
RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting

2024-514327-42-00 Phase II 2 countries Grupo Espanol De Tumores Neuroendocrinos
Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell … Recruiting

2024-515847-47-00 Phase II 2 countries Institut Gustave Roussy
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Phase III 12 countries Amgen Inc.
Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated… Recruiting

2024-515948-23-00 Phase III 1 country Intergroupe Francophone De Cancerologie Thoracique
Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re… Recruiting

2024-515201-26-00 Phase II 1 country Fundacion GECP
TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II t… Recruiting

2023-510568-11-00 Phase I/II 1 country Centre Leon Berard
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Phase III 13 countries Amgen Inc.
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Phase II 6 countries Amgen Inc.
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Phase III 16 countries Amgen Inc.
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Phase III 15 countries Amgen Inc.
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC). Ended

2024-511837-37-00 Phase II 9 countries Amgen Inc.

Showing 1–14 of 14 trials

← All drugs A–Z